SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-18-030544
Filing Date
2018-12-06
Accepted
2018-12-06 07:45:23
Documents
4
Period of Report
2018-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 Q418 8-K ANNOUNCING EXPANSION OF COLLABORATION WITH NOVARTIS ntla-8k_20181203.htm 8-K 39130
2 EX-99.1 ntla-ex991_6.htm EX-99.1 18665
3 GRAPHIC gy4xh2i34hvw000001.jpg GRAPHIC 1425982
4 GRAPHIC gy4xh2i34hvw000002.jpg GRAPHIC 1336632
  Complete submission text file 0001564590-18-030544.txt   3856192
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 181218908
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences